Valeant Offers to Buy Allergan With Pershing’s Support

Valeant Pharmaceuticals International Inc. offered to buy Allergan Inc., maker of the Botox wrinkle treatment, in a cash-and-stock deal valued at $45.7 billion in the latest step of the Canadian company’s plan to become one of the world’s largest drugmakers.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.